Clinuvel Pharmaceuticals (ASX:CUV) EPS (Basic): A$0.65 (TTM As of Dec. 2025)


ASX:CUV Clinuvel Pharmaceuticals Ltd ASX:CUV
85 GF Score
Price A$10.20
GF Value A$17.70
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Clinuvel Pharmaceuticals EPS (Basic)?

Clinuvel Pharmaceuticals ASX:CUV +2.51% 85 EPS (Basic) is A$0.65 as of Dec. 2025. GuruFocus rates ASX:CUV with a GF Score™ of 85/100 and a GF Value™ of A$17.70 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Clinuvel Pharmaceuticals's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was A$0.21. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.65.

Clinuvel Pharmaceuticals's EPS (Diluted) for the six months ended in Dec. 2025 was A$0.21. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.64.

Clinuvel Pharmaceuticals's EPS without NRI for the six months ended in Dec. 2025 was A$0.21. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 0.64.

During the past 12 months, Clinuvel Pharmaceuticals's average EPS without NRIGrowth Rate was -15.90% per year. During the past 3 years, the average EPS without NRI Growth Rate was 21.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 16.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Clinuvel Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 32.10% per year. The lowest was -120.60% per year. And the median was 13.80% per year.

Clinuvel Pharmaceuticals  (ASX:CUV) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Clinuvel Pharmaceuticals EPS (Basic) Related Terms

Clinuvel Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Clinuvel Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinuvel Pharmaceuticals EPS (Basic) Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.42 0.62 0.72 0.72

Clinuvel Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.49 0.28 0.44 0.21
ASX:CUV
85GF Score
Clinuvel Pharmaceuticals Ltd ASX:CUV
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clinuvel Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Clinuvel Pharmaceuticals's Basic EPS for the fiscal year that ended in Jun. 2025 is calculated as

Basic EPS (A: Jun. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(36.173-0)/50.076
=0.72

Clinuvel Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(10.443-0)/50.157
=0.21

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of A$0.65 mean?
Clinuvel Pharmaceuticals (ASX:CUV) has a EPS (Basic) of A$0.65 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Clinuvel Pharmaceuticals and its competitors.
Is Clinuvel Pharmaceuticals' EPS (Basic) too high?
Clinuvel Pharmaceuticals' current EPS (Basic) is A$0.65. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' EPS (Basic) compare to VRTX and REGN?
Clinuvel Pharmaceuticals' EPS (Basic) of A$0.65 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current EPS (Basic) is A$0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.70, compared to a current price of A$10.20 — trading 42.4% below its estimated fair value. The current EPS (Basic) is A$0.65. Clinuvel Pharmaceuticals' overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current EPS (Basic) is A$0.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued. The current stock price of A$10.20 is trading 42.4% below its estimated GF Value™ of A$17.70. GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for ASX:CUV:

  • EPS (Basic): A$0.65
  • GF Value™: A$17.70 vs. price of A$10.20 (42.4% below fair value)
  • GF Score™: 85/100 with 2 warning signs

No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinuvel Pharmaceuticals Business Description

Address 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
85GF Score

Get the complete analysis for ASX:CUV

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$10.20
Price
A$17.70
GF Value